These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34648691)

  • 1. Evaluation of the estimation and classification performance of NONMEM when applying mixture model for drug clearance.
    Hui KH; Lam TN
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1564-1577. PubMed ID: 34648691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covariate detection in population pharmacokinetics using partially linear mixed effects models.
    Bonate PL
    Pharm Res; 2005 Apr; 22(4):541-9. PubMed ID: 15846461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype.
    Kaila N; Straka RJ; Brundage RC
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):141-56. PubMed ID: 17053980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of mixture modeling with count data using NONMEM.
    Frame B; Miller R; Lalonde RL
    J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):167-83. PubMed ID: 14571690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of a mixture model by the degree of a missing categorical covariate when estimating clearance in NONMEM.
    Yoon S; Lim HS
    Transl Clin Pharmacol; 2019 Dec; 27(4):141-148. PubMed ID: 32095482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of type I error rates for the statistical sub-model in NONMEM.
    Wählby U; Bouw MR; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):251-69. PubMed ID: 12449498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Modified Hybrid Wald's Approximation Method for Efficient Covariate Selection in Population Pharmacokinetic Analysis.
    Zou Y; Tang F; Ng CM
    AAPS J; 2021 Mar; 23(2):37. PubMed ID: 33660056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.
    Ette EI; Onyiah LC
    Eur J Drug Metab Pharmacokinet; 2002; 27(3):213-24. PubMed ID: 12365204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses.
    Ahn JE; Birnbaum AK; Brundage RC
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):703-18. PubMed ID: 16328100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A reduction in between subject variability is not mandatory for selecting a new covariate.
    Lagishetty CV; Vajjah P; Duffull SB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
    Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
    Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.
    Duan JZ; Jackson AJ; Zhao P
    J Clin Pharmacol; 2011 Jul; 51(7):1087-100. PubMed ID: 20864622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.
    Silber HE; Kjellsson MC; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):81-99. PubMed ID: 19219538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.
    White DB; Walawander CA; Tung Y; Grasela TH
    J Pharmacokinet Biopharm; 1991 Feb; 19(1):87-112. PubMed ID: 2023111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools.
    Goulooze SC; Krekels EHJ; Hankemeier T; Knibbe CAJ
    AAPS J; 2018 Dec; 21(1):11. PubMed ID: 30565031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test.
    Xu XS; Yuan M; Yang H; Feng Y; Xu J; Pinheiro J
    AAPS J; 2017 Jan; 19(1):264-273. PubMed ID: 27761720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
    Jönsson S; Cheng YF; Edenius C; Lees KR; Odergren T; Karlsson MO
    Clin Pharmacokinet; 2005; 44(8):863-78. PubMed ID: 16029070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.